Although several Akt inhibitors are now undergoing clinical trials, only one has been evaluated in hematological malignancies to this day (GSK2110183 in multiple myeloma and chronic lymphocytic leukemia)39. This evidence concerns the gene AKT1 and AL amyloidosis.